Mar 24, 2021BioSpace: Meissa’s Intranasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses
Mar 16, 2021Meissa Announces IND Clearance for Phase 1 Study of COVID-19 Intranasal Live Attenuated Vaccine
Jan 21, 2021Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV
Oct 13, 2020Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Candidates
Jul 29, 2020San Francisco Business Times: Covid Vaccine Player Hopes to Start Clinical Trial Early Next Year
Jul 19, 2020BioSpace: Another COVID-19 Vaccine Joins the Race – This Time, it’s a Live, Weakened Virus
Jan 10, 2020Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine
Sep 25, 2019Endpoints: Meissa Obtains $30M Series A to Test Synthetic Biology Approach to 'Elusive' RSV Vaccines
Jul 11, 2017Meissa Vaccines Awarded NIH SBIR Grant to Advance IND Preparations for RSV Vaccine Candidate
Jul 11, 2017Meissa Vaccines Receives FDA Clearance of IND Application, Phase 1 Clinical Trial of MV-012-968
May 10, 2017Meissa Awarded NIH SBIR Grant to Support Development of Multivalent Human Rhinovirus Vaccine Candida
